IP Library Granted Patent US 9,017,743
Granted Patent B2
US 9,017,743 · App. 13/528,520 · Granted Apr 28, 2015

Bacterial extract for digestive or urinary tract disorders and process for its preparation

Inventors: Jacques Alain Bauer (Saint-Prex, CH); Marco Salvagni (Geneva, CH); Jean-Pierre Leon Vigroux (Bonneville, FR); Laetitia Chalvet (St Genis Pouilly, FR); Carlo Chiavaroli (Thoiry, FI)
Assignee: OM Pharma
A61K35/74Y10S435/849
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,017,743
App. No.
13/528,520
Granted
Apr 28, 2015
Kind
B2
Abstract

The present invention relates to an extract from bacterial strains useful as a treatment for disorders such as digestive or urinary tract disorders, compositions comprising the extract, and processes of making the extract from media that do not pose a risk of prion diseases.

Claims (17)

1. A method of stimulating an immune response in a subject, comprising administering to said subject, an effective amount of an extract obtained from one or more of Escherichia coli ( E. coli ) bacterial strains selected from NCTC: 8603, 8621, 8622, 8623, 9026, 9111, 9119, 9707, and 9708 and I: 081, 082, 083, 084, 085, 086, 087, 088, and 089, lysed at an initial pH greater than 12, wherein the individual bacterial strains are grown in a medium which does not pose risk of prion diseases, wherein the extract is treated so as to reduce the nucleic acids to less than 100 μg/ml, wherein said extract comprises one or more amino acids, and wherein 3-80% of said one or more amino acids is racemized from L to D, and said one or more amino acids is chosen from aspartic acid, asparagine, glutamic acid, glutamine, serine, methionine, histidine, alanine, arginine, phenylalanine, tyrosine, leucine, lysine, valine, and threonine, wherein said extract preserves and/or retains saccharide components from Escherichia coli ( E. coli ).

2. The method of claim 1 , wherein said one or more Escherichia coli ( E. coli ) bacterial strains are lysed at a pH of 12.6 to 13.4.

3. The method of claim 1 , wherein said one or more Escherichia coli ( E. coli ) bacterial strains are lysed separately or as a mixture.

4. The method of claim 1 , wherein said one or more Escherichia coli ( E. coli ) bacterial strains are cultured in a vegetal or synthetic medium.

5. The method of claim 1 , wherein said saccharide is selected from the group consisting of monosaccharides, disaccharides, and polysaccharides.

6. The method of claim 1 , wherein said extract comprises at least 0.3 mg/mL of saccharides.

7. The method of claim 1 , wherein said extract comprises between 0.3 and 4.5 mg/mL of saccharides.

8. The method of claim 1 , wherein said subject is human or a domestic mammal.

9. The method of claim 1 , wherein the subject is susceptible to a digestive or urinary tract disorder or is at risk of developing a digestive or urinary tract disorder.

10. The method of claim 1 , wherein said extract improves the survival rate of subjects having a urinary tract infection by at least 70%.

11. The method of claim 10 , wherein the survival rate is at least 80%.

12. The method of claim 10 , wherein the survival rate is at least 90%.

13. The method of claim 1 , wherein said extract improves the survival rate of subjects infected with Salmonella typhimurium by at least 70%.

14. The method of claim 13 , wherein the survival rate is at least 80%.

15. The method of claim 13 , wherein the survival rate is at least 90%.

16. The method of claim 1 , wherein the extract is obtained from a mixture of Escherichia coli ( E. Coli ) bacterial strains NCTC: 8603, 8621, 8622, 8623, 9026, 9111, 9119, 9707, and 9708 and I: 081, 082, 083, 084, 085, 086, 087, 088, and 089.

17. The method of claim 9 , wherein said digestive or tract disorder is a tract disorder selected from the group consisting of urethritis, tubulo-interstitial nephritis, obstructive pyelonephritis, urinary tract infections due to obstructive and reflux uropathy, cystitis, chronic cystitis, prostatitis, chronic prostatitis, prostatocystitis, female pelvic inflammatory diseases, Crohn's disease, and irritable bowel syndrome.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 16, 2012
From: BAUER, JACQUES ALAIN; SALVAGNI, MARCO; VIGROUX, JEAN-PIERRE LEON; CHALVET, LAETITIA; CHIAVAROLI, CARLO
To: OM PHARMA
Reel/Frame 028558/0679 →
Continuity (3)
Division 12530159
Provisional Application 60904787 · Mar 5, 2007
Related Publication 20130022695A1 · Jan 24, 2013